Department of Health Care Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki city, Okayama 701-0192, Japan.
Division of Endoscopy and Ultrasonography, Department of Clinical Pathology and Laboratory Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki city, Okayama 701-0192, Japan.
J Smooth Muscle Res. 2023;59:14-27. doi: 10.1540/jsmr.59.14.
Esophageal achalasia is classified into three subtypes according to manometric findings. Since several factors, including clinical characteristics and treatment response, have been reported to differ among the subtypes, the underlying pathogenesis may also differ. However, a comprehensive understanding regarding the differences is still lacking. We therefore performed a systematic review of the differences among the three subtypes of achalasia to clarify the current level of comprehension. In terms of clinical features, type III, which is the least frequently diagnosed of the three subtypes, showed the oldest age and most severe symptoms, such as chest pain. In contrast, type I showed a higher prevalence of lung complications, and type II showed weight loss more frequently than the other types. Histopathologically, type I showed a high loss of ganglion cells in esophagus, and on a molecular basis, type III had elevated serum pro-inflammatory cytokine levels. In addition to peristalsis and the lower esophageal sphincter (LES) function, the upper esophageal sphincter (UES) function of achalasia has attracted attention, as an impaired UES function is associated with severe aspiration pneumonia, a fatal complication of achalasia. Previous studies have indicated that type II shows a higher UES pressure than the other subtypes, while an earlier decline in the UES function has been confirmed in type I. Differences in the treatment response are also crucial for managing achalasia patients. A number of studies have reported better responses in type II cases and less favorable responses in type III cases to pneumatic dilatation. These differences help shed light on the pathogenesis of achalasia and support its clinical management according to the subtype.
食管失弛缓症根据测压结果可分为三种亚型。由于已有报道称各亚型之间存在包括临床特征和治疗反应在内的多种差异,其潜在发病机制也可能不同。然而,对于这些差异仍缺乏全面的了解。因此,我们对三种亚型的食管失弛缓症进行了系统综述,以阐明目前对其的认识程度。在临床特征方面,三种亚型中诊断率最低的 III 型年龄最大,症状最严重,如胸痛。相比之下,I 型更常出现肺部并发症,而 II 型比其他类型更常出现体重减轻。组织病理学上,I 型显示食管神经节细胞大量缺失,在分子基础上,III 型血清促炎细胞因子水平升高。除了蠕动和食管下括约肌(LES)功能外,食管失弛缓症的上食管括约肌(UES)功能也受到关注,因为UES 功能障碍与严重的吸入性肺炎有关,这是食管失弛缓症的一种致命并发症。先前的研究表明,II 型的 UES 压力高于其他亚型,而 I 型的 UES 功能更早下降。治疗反应的差异对食管失弛缓症患者的管理也至关重要。多项研究报道,II 型对气囊扩张治疗的反应更好,而 III 型的反应较差。这些差异有助于阐明食管失弛缓症的发病机制,并支持根据亚型进行临床管理。